NCT03180528View on ClinicalTrials.gov

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 7, 2018

Primary Completion Date

July 7, 2020

Study Completion Date

December 31, 2020

Conditions
Skin Basal Cell Carcinoma
Interventions
DRUG

Remetinostat

Applied topically under bandage occlusion

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

Sponsors

Collaborators (1)

Medivir
All Listed Sponsors
collaborator

Medivir

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

American Skin Association

OTHER

lead

Kavita Sarin

OTHER

NCT03180528 - Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer | Biotech Hunter | Biotech Hunter